Innovent Biologics, Inc. (HKG:1801)
Hong Kong
· Delayed Price · Currency is HKD 39.95
-0.70 (-1.72%)
Mar 4, 2025, 10:33 AM HKT
Innovent Biologics Employees
Innovent Biologics had 4,872 employees as of December 31, 2023. The number of employees decreased by 422 or -7.97% compared to the previous year.
Employees
4,872
Change (1Y)
-422
Growth (1Y)
-7.97%
Revenue / Employee
1.52M HKD
Profits / Employee
-261.61K HKD
Market Cap
66.59B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| BeiGene | 10,600 |
| JD Health International | 3,118 |
| Hansoh Pharmaceutical Group Company | 9,123 |
| WuXi Biologics | 12,740 |
| Alibaba Health Information Technology | 1,435 |
| Akeso | 2,778 |
| Sinopharm Group | 115,959 |
| Sino Biopharmaceutical | 25,806 |
Innovent Biologics News
- 8 days ago - NMPA Accepts NDA and Grants Priority Review Designation to Innovent's Ipilimumab Injection, China's First Domestic CTLA-4 Inhibitor, in Combination with Sintilimab as Neoadjuvant Treatment for Colon Cancer - PRNewsWire
- 15 days ago - Innovent Receives Second Fast Track Designation from the U.S. FDA for IBI363 (PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in Squamous Non-Small Cell Lung Cancer - PRNewsWire
- 6 weeks ago - Innovent Biologics Inc (IVBIY) Announces NMPA Approval of Limertinib for Lung Cancer Treatment - GuruFocus
- 6 weeks ago - Innovent Biologics Inc (IVBIY) Unveils Strategic Growth Plans at J.P. Morgan Healthcare Conference - GuruFocus
- 6 weeks ago - Innovent and ASK Pharm Jointly Announce NMPA Approval of Limertinib, a Third-generation EGFR TKI for the Treatment of Lung Cancer - PRNewsWire
- 6 weeks ago - Innovent Presents at the 43rd Annual J.P. Morgan Healthcare Conference - PRNewsWire
- 6 weeks ago - Innovent Biologics Inc (IVBIY) Secures Breakthrough Therapy Designation for IBI343 in Advanced ... - GuruFocus
- 6 weeks ago - Innovent Receives NMPA Breakthrough Therapy Designation for IBI343 (Anti-CLDN18.2 ADC) as Monotherapy for Advanced Pancreatic Cancer - PRNewsWire